Correction: Strategies for Combination Therapy to Address Resistance to Immune Checkpoint Inhibitors
-
By
-
Besan H. Alsaafeen
-
Bassam R. Ali
-
Eyad Elkord
-
April 24, 2026
-
Objective:
To correct inaccuracies in the previously published table of FDA-approved immune checkpoint inhibitor combination therapies.
Key Findings:
- Certain FDA-approved ICI combination therapies were omitted in the original publication.
- The corrected table now accurately reflects the FDA approvals as of July 2024.
- Clarifications were made to ensure consistency in the text regarding pembrolizumab's approval.
Interpretation:
The corrections enhance the accuracy and reliability of the information regarding combination therapies for immune checkpoint inhibitors.
Limitations:
- The article only addresses corrections and does not present new research findings.
- Focus is limited to FDA-approved therapies, excluding other potential combinations.
Conclusion:
The corrections provide a comprehensive and accurate overview of FDA-approved combination immunotherapies involving ICIs.
